Government partners with Mounjaro maker to tackle obesity
The move could see patients accessing care at pharmacies or by using online platforms.
The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily.
This includes through community services, in pharmacies and online.
Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting.
Under the agreement, the Government will contribute up to £50 million in UK-wide investment.
Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding.
Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK.
Eligible patients could be able to access these innovative services by summer 2026, the Government said.
Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions.
'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added.
'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments.
'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.'
Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'.
They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added.
NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference.
'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.'
Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.'
Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies.
'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said.
'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support.
'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care.
'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes.
'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.'
News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs.
People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug.
The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities.
Over the next three years, about 240,000 patients are expected to be eligible for the treatment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
25 minutes ago
- Medscape
Drug Combinations for CVDs Tied to Bullous Pemphigoid Risk
TOPLINE: A case-control study revealed that combinations of drugs for cardiovascular diseases and hypertension were frequently prescribed before a diagnosis of bullous pemphigoid (BP), but the risk associated with combinations did not exceed that associated with individual agents. The most common drug combinations included angiotensin-converting enzyme (ACE) inhibitors with statins and antiplatelets with statins. METHODOLOGY: Researchers conducted a nested case-control study using healthcare records from the Clinical Practice Research Datalink between 1998 and 2021 and analysed 16,844 BP cases and 79,493 age- and sex-matched control individuals having no BP diagnosis at the index date (the first date a BP diagnosis code was recorded). Association rule mining (ARM) identified the 10 most common drug class or active substance pairs prescribed to cases or control individuals on the same day and within 6 months before the index date. In the sensitivity analysis, researchers identified medication pairs prescribed within 30 days of each other and during the 6 months preceding the index date. Researchers quantified how often two drugs are co-prescribed compared with their independent prescribing by calculating a lift. They then derived the fold change (FC) as the ratio of a lift in cases vs control individuals. The analysis included multivariable conditional logistic regression to estimate the risk for BP following drug combinations and their constituent drugs. TAKEAWAY: The most frequent drug combinations associated with an increased risk for BP were ACE inhibitors-statins (FC of the lifts in the main analysis vs sensitivity analysis: 1.31 vs 1.18), antiplatelets-statins (1.23 vs 1.11), proton pump inhibitors (PPI)-antiplatelets (1.22 vs 1.14), PPI-statins (1.22 vs 1.14), and ACE inhibitors-antiplatelets (1.20 vs 1.09). For drug substances, combinations with a greater lift in BP cases were simvastatin-ramipril (FC, 1.30), simvastatin-aspirin (FC, 1.21), and ramipril-aspirin (FC, 1.19). After adjusting for BP-associated drugs, the Charlson Comorbidity Index, and relevant confounders, the increased risk remained significant for these drug class combinations: antiplatelets-statins (odds ratio [OR], 1.20), ACE inhibitors-statins (OR, 1.16), PPI-statins (OR, 1.22), ACE inhibitors-antiplatelets (OR, 1.26), and PPI-antiplatelets (OR, 1.43; P < .001 for all). The risk for BP associated with these frequently prescribed drug combinations was lower than the risk linked to each constituent drug at both class and substance levels. In both main and sensitivity analyses, patients who developed BP were more likely than control individuals to have received combinations of cardiovascular or antihypertensive drugs before diagnosis. IN PRACTICE: "The ARM algorithm exploratory analysis identified the most commonly prescribed drug combinations prior to BP. Logistic regression confirmed drug combinations for CVDs [cardiovascular diseases] or hypertension associated with increased BP risk," the authors wrote. "The increased BP risk following reported combinations was modest and was not greater than their constituent drugs. Given that the number of patients with BP is low, we do not suggest avoiding the reported drugs but instead being on the lookout for any skin reactions following treatments for CVDs or hypertension," they concluded. SOURCE: This study was led by Mikolaj Swiderski, University of Nottingham, Nottingham, England. It was published online on August 06, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The ARM algorithm considered only the frequency of prescriptions to obtain drug combinations. Additionally, the algorithm demonstrated limited clinical value, linking only half of the inferred drug class combinations with BP and failing to capture the sequence or precise timing of prescriptions. It also lacked dosage and treatment duration data, and as an exploratory tool, ARM could not establish causal relationships between drug exposures and the risk for BP. DISCLOSURES: This research was supported by the National Institute for Health and Care Research grant via the Research for Patient Benefit Programme. Swiderski reported receiving salary funding from this grant. Another author reported receiving salary funding from King's College London, University of Nottingham, and the National Institute for Health and Care Research East Midlands scholarship scheme. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
25 minutes ago
- Medscape
A1c Testing in EDs Can Spot Undiagnosed Diabetes Cases
TOPLINE: Among adults aged 30 years or older presenting to the emergency department (ED) without a prior diagnosis of type 2 diabetes (T2D), A1c testing combined with the Finnish Diabetes Risk Score (FINDRISC) identified a substantial proportion with prediabetes or diabetes — especially among those from ethnically diverse populations. METHODOLOGY: Researchers in England conducted a prospective study from December 2021 to December 2022 to determine the prevalence of glucose intolerance among 1382 individuals aged 30 years or older (45.1% men) who did not have a known diagnosis of diabetes and presented to the ED of a hospital in Manchester. They also tested the utility of the FINDRISC in predicting the risk for diabetes in high-risk individuals. Data on demographics, lifestyle factors, physical measurements, and A1c levels were collected, and the FINDRISC assessment was conducted by trained staff. Patients were classified as those having normal glucose tolerance, prediabetes, or diabetes according to both National Institute for Health and Care Excellence (NICE) and American Diabetes Association (ADA) guidelines. TAKEAWAY: On the basis of the NICE criteria, 80.1% of attendees had normal glucose tolerance, 11.6% had prediabetes, and 8.3% had diabetes; on the basis of the ADA criteria, the corresponding percentages were 61.3%, 30.4%, and 8.3%, respectively. Each unit increase in the FINDRISC was linked to an 8% (5%-12%) higher risk for prediabetes and a 16% (10%-23%) higher risk for diabetes, as per the NICE criteria, with similar findings seen for the ADA criteria as well; the risk remained elevated even after adjustment for confounders. Compared with White individuals, British South Asian and other minority groups showed nearly twice the risk for prediabetes (relative risk ratio [RRR], 1.94; 95% CI, 1.11-3.38) and three times the risk for diabetes (RRR, 2.80; 95% CI, 1.61-4.84). IN PRACTICE: "The considerable prevalence of undiagnosed diabetes within our patient population highlights the critical need for routine HbA1c screening in this setting, which may be the only place where hard-to-reach individuals may attend for healthcare," the authors wrote. SOURCE: This study was led by Edward B. Jude, Tameside and Glossop Integrated Care, NHS Foundation Trust, Manchester, England. It was published online on August 06, 2025, in Diabetes Therapy. LIMITATIONS: The accuracy of A1c testing can be affected by conditions altering the quality or quantity of haemoglobin, such as anaemia or haemoglobinopathies, potentially leading to an underestimation of diabetes prevalence. Selection bias may exist as the study focused only on patients who underwent bloodwork in the ED. The single-centre nature of the study limited the generalisability of the results. DISCLOSURES: This study received partial funding from Sanofi Pharmaceuticals and Novo Nordisk. One author was supported by the 4Ward North Wellcome Trust Clinical Research Training Fellowship, and another author declared receiving travel and research grants from the funding agencies and other sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
'Walking cricket has changed my life'
A group of over-50's walking cricket players say the sport is helping with their physical and mental health issues. Bexhill Walking Cricket Club meet every Friday for an indoor match of the sport, which is played with a soft ball at a walking pace. Players range from people in their early 60s to mid 80s. "We've got people who have lost huge amounts of weight, and players with dementia and just some who have expanded their social circle," says chairman Laurie Ray. Andy Evans, who has prostate cancer, said the activity has helped him "mentally and physically". He said he was "well overweight", and he had been told he needed to shed some pounds. "It's changed my life now," he said. "I'm quite lucky as (the cancer) is manageable now, but this has helped my health should I ever need an operation." The club have faced other walking cricket clubs in the area, but Mr Ray says it's "about exercise more than results". John Martin, aged 80, is one of the club's oldest players. "I do walking football, table tennis and this. I just love all sports," he said. "If more people did this, their health would be so much better." Bexhill Walking Cricket Club meet on Friday's at 0930 at Bexhill Leisure Centre. Follow BBC Sussex on Facebook, X and Instagram. Send your story ideas to southeasttoday@ or WhatsApp us on 08081 002250. Walking cricket to be prescribed on NHS
